title: [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
abstract: OBJECTIVE
  To evaluate the resolution rate in patients with symptomatic vitreomacular traction (≤ 1500 μm) with or without macular holes (≤ 400 μm) after therapy with intravitreal ocriplasmin (Jetrea®) injection in a clinical setting.
  
  
  METHODS
  Until now we have prospectively examined 21 eyes of 21 consecutive patients with symptomatic vitreomacular traction with or without macular holes who underwent intravitreal operative injection of 0.1 ml ocriplasmin. The best corrected visual acuity and high-resolution optical coherence tomography (SD-OCT) ultrastructural parameters were measured before injection and again 1, 3 and 4 months after treatment. The numbers of resolved vitreomacular traction and closed macular holes were documented.
  
  
  RESULTS
  Vitreomacular traction was resolved in 15 out of 21 (71 %) eyes. Of the five eyes which initially presented with vitreomacular traction with macular holes, all showed resolution of vitreomacular traction but only two of the macular holes were closed. The average best corrected visual acuity was 0.38 logMAR (± 0.23) at baseline and 0.43 logMAR (± 0.28), 0.38 logMAR (± 0.27) and 0.36 logMAR (± 0.24) 1, 3 and 4 months after injection, respectively. The average foveal thickness was 355.95 μm (± 114.53 μm) at baseline, reducing to 304.61 μm (± 100.91 μm), 308.00 μm (±76.17 μm) and 277.50 μm (± 26.24 μm) after 1, 3 and 4 months, respectively.
  
  
  CONCLUSIONS
  In this ongoing study there was a high percentage of resolution of vitreomacular traction (71 %) 1 month after intravitreal operative injection of Jetrea® and closure of two out of five macular holes. This was further associated with stabilization of visual acuity and reduction of foveal thickness. Further investigations are necessary to document the effectiveness of the pharmacological vitreolysis in a clinical setting.
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland. Mathias.Maier@mri.tum.de.
authors.forename: M
authors.initials: M
authors.lastname: Maier
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Abraham
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Frank
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
authors.forename: N
authors.initials: N
authors.lastname: Feucht
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
authors.forename: C P
authors.initials: CP
authors.lastname: Lohmann
mesh_terms: D000368:Aged; D000933:Antifibrinolytic Agents / Q000008:administration & dosage; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D010865:Pilot Projects; D012167:Retinal Perforations / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D000267:Tissue Adhesions / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome; D014786:Vision Disorders / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control*; D014792:Visual Acuity; D020255:Vitreous Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000933:Antifibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin
keywords: Indications; Intravitreal treatment; Retinal thickness; Visual acuity; Vitreolysis